Atlantic Shores Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kakar, Rishi
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
NCT06608641: Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Active, not recruiting
3
490
US
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Jina Pharmaceuticals Inc., Novum Pharmaceutical Research Services
Bipolar 1 Disorder
06/25
12/25
APPROACH, NCT06564818: "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Recruiting
3
220
US
CYB003, Psychological Support, Placebo
Cybin IRL Limited, Worldwide Clinical Trials
Major Depressive Disorder
03/26
05/26
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/26
12/26
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Completed
2
359
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
12/24
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
10/25
10/25
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting
N/A
300
Canada, US, RoW
ERG assessment (RSPA)
diaMentis Inc.
Schizophrenia, Bipolar I Disorder
12/24
12/24
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kakar, Rishi
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
NCT06608641: Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Active, not recruiting
3
490
US
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Jina Pharmaceuticals Inc., Novum Pharmaceutical Research Services
Bipolar 1 Disorder
06/25
12/25
APPROACH, NCT06564818: "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Recruiting
3
220
US
CYB003, Psychological Support, Placebo
Cybin IRL Limited, Worldwide Clinical Trials
Major Depressive Disorder
03/26
05/26
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/26
12/26
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Completed
2
359
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
12/24
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
10/25
10/25
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting
N/A
300
Canada, US, RoW
ERG assessment (RSPA)
diaMentis Inc.
Schizophrenia, Bipolar I Disorder
12/24
12/24
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24

Download Options